HB441 increases Hawaii’s cigarette excise tax from 16 cents to 18 cents per cigarette and little cigar beginning January 1, 2026. The bill also revises the revenue allocation rules so that the new 2-cent increase is directed to the Hawaii cancer research special fund, rather than the general cigarette-tax distribution formula used for other health-related funds.
The measure is framed as a funding stabilization bill for the University of Hawaii Cancer Center, also known as the Hawaii Cancer Research Center. The legislature states that declining smoking rates have reduced cigarette-tax collections, which has in turn weakened support for cancer research, operations, and debt service on revenue bonds issued to build the center. To address that, the bill specifies that money deposited under the new tax bracket must be used for cancer research and, for a defined period, exclusively for debt service on capital expenditures and building maintenance.
Impact
HB441 amends section 245-3 of the Hawaii Revised Statutes to raise the cigarette and little cigar tax rate and amends section 245-15 to change how cigarette-tax revenues are distributed. It creates a new tax tier for cigarettes and little cigars sold on or after January 1, 2026, and directs the additional revenue to the Hawaii cancer research special fund, with a portion earmarked for debt service and building maintenance through June 30, 2030, then partially thereafter. The bill preserves existing allocations to the trauma system, community health centers, and emergency medical services special funds, but shifts the incremental revenue from the tax increase to cancer research funding.
Sentiment
The bill appears to have broad support among legislative committees and conferees. It passed Senate Higher Education, Senate Health and Human Services, and Senate Ways and Means with favorable votes, and later passed House and Senate conference unanimously. The committee pattern suggests the measure was viewed positively as a public-health and funding measure, especially for cancer research and related health infrastructure.
Contention
The main policy issue is not whether to fund cancer research, but how to do so and at what cost. Supporters emphasize the public-health rationale for using cigarette-tax revenue to sustain the cancer center, protect bond debt service, and maintain operations despite declining smoking-related revenue. Any opposition would likely center on the tax increase itself, including concerns about higher costs for tobacco consumers, the use of a regressive excise tax, or whether earmarking the new revenue for one institution is preferable to broader health-program distribution. The available vote history shows limited recorded dissent, with only one no vote in an early Senate committee and otherwise strong support.